Teva-Barr deal complete
This article was originally published in The Tan Sheet
Executive Summary
Teva Pharmaceutical Industries' $7.5 billion acquisition of Barr Laboratories is complete, the Jerusalem-based generics firm says Dec. 23. Teva will pay an additional $1.5 in debt settlement, and receive the rights to Barr's OTC emergency contraceptive Plan B and its women's health portfolio (1"The Tan Sheet" July 21, 2008, In Brief). Under an antitrust settlement with the Federal Trade Commission announced Dec. 19, the combined entity will divest some generic drugs to Watson Pharmaceuticals and Qualitest Pharmaceuticals to complete the acquisition